Five things for pharma marketers to know: Monday, August 29, 2016
1. Mylan said it would launch a generic version of its EpiPen that will cost half of what the branded product costs. The drugmaker has been criticized for the price hikes of the EpiPen and an announcement it made last week to offer additional copay support to patients in response to the scrutiny was also criticized. (Reuters)
2. Almost 9 of 10 experts who help develop National Comprehensive Cancer Network guidelines reported at least one financial conflict of interest in 2014, a new study found. (Medscape)
3. Sanofi and Regeneron Pharmaceuticals said Praluent, their PCSK9 inhibitor, met the targets in a new clinical trial. The drug, approved last year, reduced cholesterol in patients with a hereditary high-cholesterol disorder as well as lowered the need for a procedure to cut cholesterol levels. (WSJ)
4. Purdue Pharma has reportedly refused to turn over information it gathers about suspected criminal trafficking of OxyContin, according to the New Hampshire attorney general. The state has one of the nation's highest rates of opioid prescriptions and addition. (LAT)
5. ICYMI: A nonprofit pharmaceutical organization called the Drugs for Neglected Diseases initiative has brought six new drugs to market, using $290 million. The nonprofit uses a product development partnership model that leans heavily on collaboration with universities, governments, and the drug industry. (Nature)
Got a news tip or a pitch for the morning roundup? Email email@example.com.